Amarillo Biosciences, Inc. (AMAR) is a specialty biopharmaceutical company dedicated to the development and commercialization of interferon alpha as a human therapeutic. AMAR presently owns or licenses 4 US patents related to the low-dose oral delivery of interferon. AMAR also owns one issued US patent concerning Maxisal®, a dietary supplement for the relief of dry mouth. The Company has completed over 100 studies in humans and animals. AMAR’s low-dose oral technology reduces or eliminates side effects associated with high-dose injectable interferon.
The Company will focus on regulatory approval and global commercialization of low-dose oral interferon treatment of influenza, a potential multi-billion dollar market opportunity. AMAR is also working toward FDA approval of oral interferon for prevention of relapse in patients with chronic active hepatitis C virus infection.
AMAR stock is publicly traded in the United States in the OTCBB market under the symbol: AMAR.OB. In Germany, the Company stock is publicly traded on the Frankfurt, Stuttgart, Berlin-Bremen and Xetra exchanges as FZX WKN 917640.
For additional Information, please contact:
……………………………..Bernard H. CohenChief Financial OfficerAmarillo Biosciences, Inc.4134 Business Park DriveAmarillo, TX 79110Phone: 806-376-1741Email: